Omega-3 fatty acids and cardiovascular outcomes, what the named trials actually show

Key takeaways

• REDUCE-IT (icosapent ethyl 4 g/day, n equal to 8,179, statin-treated adults with elevated triglycerides and high cardiovascular risk) reported a 25 percent relative reduction in the primary 5-point MACE composite over a median 4.9 year follow-up.
• VITAL (1 g/day EPA+DHA fish oil capsule, n equal to 25,871, general-population primary prevention) did not significantly reduce the primary cardiovascular composite over 5.3 years; a benefit on myocardial infarction was observed in pre-specified secondary analyses.
• ASCEND (1 g/day EPA+DHA, n equal to 15,480, adults with diabetes without cardiovascular disease) did not significantly reduce serious vascular events over 7.4 years.
• STRENGTH (carboxylic acid formulation 4 g/day EPA+DHA, n equal to 13,078) was stopped early for futility in 2020; the trial showed no benefit on cardiovascular events vs. corn oil placebo. The contrast with REDUCE-IT raised questions about the role of the mineral oil placebo and the EPA-only vs. mixed-EPA-DHA formulation.
• Omega-3 supplementation at 4 g/day reliably lowers serum triglycerides by approximately 25 to 30 percent. Atrial fibrillation incidence is modestly increased on high-dose omega-3, a labeled finding in REDUCE-IT and STRENGTH.

What omega-3 supplementation is

Omega-3 fatty acids are a class of polyunsaturated fatty acids defined by a double bond at the third carbon from the methyl end of the chain. The cardiovascular literature focuses primarily on two long-chain omega-3s: eicosapentaenoic acid (EPA, 20:5n-3) and docosahexaenoic acid (DHA, 22:6n-3). Marine fish (salmon, sardines, mackerel, anchovy) are the dietary source. Supplements include fish oil (mixed EPA + DHA in ethyl ester or natural triglyceride form), krill oil (phospholipid-bound EPA + DHA), algae oil (DHA, sometimes with EPA), and the FDA-approved purified products icosapent ethyl (Vascepa, EPA only) and omega-3-acid ethyl esters (Lovaza, EPA + DHA).

The Office of Dietary Supplements at NIH publishes a fact sheet documenting the dietary forms, conversion rates from plant-derived alpha-linolenic acid (ALA, 18:3n-3, with low conversion to EPA and very low conversion to DHA), and the Institute of Medicine adequate intake levels .

REDUCE-IT: the icosapent ethyl trial

REDUCE-IT was a randomized, double-blind, placebo-controlled trial of icosapent ethyl 4 g/day (purified EPA ethyl ester) in 8,179 statin-treated adults with elevated triglycerides (135 to 499 mg/dL) and either established cardiovascular disease or diabetes plus risk factors. Median follow-up was 4.9 years. The primary 5-point MACE composite (cardiovascular death, non-fatal MI, non-fatal stroke, coronary revascularization, unstable angina) was reduced 25 percent (HR 0.75, 95 percent CI 0.68 to 0.83, p less than 0.001) .

REDUCE-IT supported the FDA's expansion of the icosapent ethyl (Vascepa) indication in December 2019 to include reduction of cardiovascular risk in adults with elevated triglycerides on statin therapy and either established cardiovascular disease or diabetes plus risk factors . The trial used a mineral oil placebo, which subsequent analyses suggested may have produced small adverse effects on lipid markers in the placebo arm. The magnitude of the placebo-arm effect on the headline result is contested in the literature.

VITAL and ASCEND: general-population trials

VITAL randomized 25,871 adults aged 50 or older (men) or 55 or older (women) without cardiovascular disease or cancer to omega-3 1 g/day (840 mg EPA+DHA), vitamin D 2000 IU/day, both, or placebo, in a 2x2 factorial design. Median follow-up was 5.3 years. The primary cardiovascular composite was not significantly reduced (HR 0.92, 95 percent CI 0.80 to 1.06). Pre-specified secondary analysis showed a 28 percent reduction in myocardial infarction (HR 0.72, 95 percent CI 0.59 to 0.90) but no reduction in stroke or cardiovascular death .

ASCEND randomized 15,480 adults with diabetes without cardiovascular disease to omega-3 1 g/day or placebo. Over 7.4 years, the primary serious vascular events composite was not significantly reduced (HR 0.97, 95 percent CI 0.87 to 1.08) . The two trials together suggest that the general-population, lower-dose omega-3 supplementation offers little or no cardiovascular benefit on top of standard care, in contrast to the high-dose, high-risk REDUCE-IT population.

STRENGTH and the EPA vs. EPA+DHA question

STRENGTH was a randomized trial of omega-3 carboxylic acid 4 g/day (mixed EPA + DHA) vs. corn oil placebo in 13,078 statin-treated adults with elevated cardiovascular risk and elevated triglycerides. The trial was stopped early for futility in January 2020. The primary 5-point MACE composite was not reduced (HR 0.99, 95 percent CI 0.90 to 1.09). Atrial fibrillation incidence was 2.2 percent on omega-3 vs. 1.3 percent on placebo (HR 1.69) .

The contrast between REDUCE-IT and STRENGTH is one of the most discussed in modern cardiovascular trials. Possible explanations include: the EPA-only formulation in REDUCE-IT vs. the EPA+DHA mix in STRENGTH; the mineral-oil placebo in REDUCE-IT vs. corn-oil placebo in STRENGTH; and the differing study populations. The published commentary literature does not converge on a single explanation, and the FDA approval for icosapent ethyl reflects the REDUCE-IT result for that specific product .

Triglycerides, lipid markers, and the dose-response

Omega-3 supplementation reliably lowers serum triglycerides at higher doses. The MARINE trial demonstrated approximately 33 percent reduction in fasting triglycerides on icosapent ethyl 4 g/day vs. placebo in adults with severe hypertriglyceridemia . The ANCHOR trial demonstrated similar reductions in adults with mixed dyslipidemia on statin therapy. The triglyceride-lowering effect is the basis for the original Vascepa and Lovaza approvals; the cardiovascular outcomes indication came later for Vascepa specifically.

At lower doses (typical OTC fish-oil capsule, 1 g/day with 300 to 500 mg EPA+DHA), the triglyceride effect is small. Omega-3 supplementation does not consistently lower LDL cholesterol; in some trials high-dose mixed EPA+DHA modestly raises LDL.

Atrial fibrillation signal

Higher-dose omega-3 supplementation is associated with a small but reproducible increase in atrial fibrillation incidence. REDUCE-IT reported atrial fibrillation in approximately 5.3 percent of the icosapent ethyl arm vs. 3.9 percent of placebo. STRENGTH reported a 1.69-fold increase. The Lombardi et al. 2021 meta-analysis pooled trials of omega-3 supplementation across cardiovascular outcomes trials and reported an overall increase in atrial fibrillation incidence with omega-3 .

The signal is small in absolute terms but consistent. The Vascepa label includes a precaution on atrial fibrillation, particularly in patients with prior atrial fibrillation or risk factors .

What the evidence does not show

• Omega-3 supplementation has not been shown to extend lifespan in any randomized trial.
• OTC fish oil at 1 g/day does not have consistent cardiovascular outcome data outside the high-risk REDUCE-IT-style population.
• Krill oil and algae oil at typical OTC doses have not been tested in cardiovascular outcome trials at the scale of VITAL or REDUCE-IT.
• Omega-3 supplementation has not been shown to treat depression, ADHD, or cognitive decline in trials specifically powered for those endpoints.